Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxen Sodium/Caffeine FDC for Dental Pain
NCT05485805Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Aprol and caffeine in odontalgia (5 arms), sponsored by Bayer. Primary endpoint: Sum of Pain Intensity Difference Over 8 Hours Post-dose. Started Sep 2022; status: completed.
02
Drugs
Aprolcaffeine
03
Conditions
odontalgia
Beyond the preview
Go deeper on NCT05485805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485805.